IGHE and asthma: As previously mentioned, blocking free IgE omalizumab interrupts the IgE-mediated asthma inflammatory cascade at an early stage, thus reducing both early and late asthmatic responses, and improving lung function, asthma control and decreasing the number of exacerbations.